These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

808 related articles for article (PubMed ID: 23225012)

  • 21. α-Synuclein and Lewy pathology in Parkinson's disease.
    Kalia LV; Kalia SK
    Curr Opin Neurol; 2015 Aug; 28(4):375-81. PubMed ID: 26110807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Accelerated formation of alpha-synuclein oligomers by concerted action of the 20S proteasome and familial Parkinson mutations.
    Lewis KA; Yaeger A; DeMartino GN; Thomas PJ
    J Bioenerg Biomembr; 2010 Feb; 42(1):85-95. PubMed ID: 20148295
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physiological and pathological role of alpha-synuclein in Parkinson's disease through iron mediated oxidative stress; the role of a putative iron-responsive element.
    Olivares D; Huang X; Branden L; Greig NH; Rogers JT
    Int J Mol Sci; 2009 Mar; 10(3):1226-60. PubMed ID: 19399246
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting alpha-synuclein for the treatment of Parkinson's disease.
    Rohn TT
    CNS Neurol Disord Drug Targets; 2012 Mar; 11(2):174-9. PubMed ID: 22483285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A deadly spread: cellular mechanisms of α-synuclein transfer.
    Steiner JA; Angot E; Brundin P
    Cell Death Differ; 2011 Sep; 18(9):1425-33. PubMed ID: 21566660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting α-synuclein for PD Therapeutics: A Pursuit on All Fronts.
    Teil M; Arotcarena ML; Faggiani E; Laferriere F; Bezard E; Dehay B
    Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32138193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular mechanisms of alpha-synuclein neurodegeneration.
    Waxman EA; Giasson BI
    Biochim Biophys Acta; 2009 Jul; 1792(7):616-24. PubMed ID: 18955133
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel conformation-selective alpha-synuclein antibodies raised against different in vitro fibril forms show distinct patterns of Lewy pathology in Parkinson's disease.
    Covell DJ; Robinson JL; Akhtar RS; Grossman M; Weintraub D; Bucklin HM; Pitkin RM; Riddle D; Yousef A; Trojanowski JQ; Lee VM
    Neuropathol Appl Neurobiol; 2017 Dec; 43(7):604-620. PubMed ID: 28386933
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Could α-synuclein amyloid-like aggregates trigger a prionic neuronal invasion?
    Busquets MA; Espargaró A; Estelrich J; Sabate R
    Biomed Res Int; 2015; 2015():172018. PubMed ID: 25866763
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapeutic interventions in Parkinson's disease: Focus on α-Synuclein.
    Ganguly U; Singh S; Chakrabarti S; Saini AK; Saini RV
    Adv Protein Chem Struct Biol; 2022; 129():381-433. PubMed ID: 35305723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The central theme of Parkinson's disease: α-synuclein.
    Ozansoy M; Başak AN
    Mol Neurobiol; 2013 Apr; 47(2):460-5. PubMed ID: 23180276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prion-like propagation of pathology in Parkinson disease.
    Volpicelli-Daley L; Brundin P
    Handb Clin Neurol; 2018; 153():321-335. PubMed ID: 29887143
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Misfolded α-synuclein and Toll-like receptors: therapeutic targets for Parkinson's disease.
    Béraud D; Maguire-Zeiss KA
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1(0 1):S17-20. PubMed ID: 22166424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathological biochemistry of alpha-synucleinopathy.
    Iwatsubo T
    Neuropathology; 2007 Oct; 27(5):474-8. PubMed ID: 18018483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Observation of an α-synuclein liquid droplet state and its maturation into Lewy body-like assemblies.
    Hardenberg MC; Sinnige T; Casford S; Dada ST; Poudel C; Robinson EA; Fuxreiter M; Kaminksi CF; Kaminski Schierle GS; Nollen EAA; Dobson CM; Vendruscolo M
    J Mol Cell Biol; 2021 Aug; 13(4):282-294. PubMed ID: 33386842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. α-Synuclein aggregation and transmission in Parkinson's disease: a link to mitochondria and lysosome.
    Wang R; Sun H; Ren H; Wang G
    Sci China Life Sci; 2020 Dec; 63(12):1850-1859. PubMed ID: 32681494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Decreased AQP4 Expression Aggravates ɑ-Synuclein Pathology in Parkinson's Disease Mice, Possibly via Impaired Glymphatic Clearance.
    Cui H; Wang W; Zheng X; Xia D; Liu H; Qin C; Tian H; Teng J
    J Mol Neurosci; 2021 Dec; 71(12):2500-2513. PubMed ID: 33772424
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
    Perfeito R; Cunha-Oliveira T; Rego AC
    Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain.
    Roberts RF; Wade-Martins R; Alegre-Abarrategui J
    Brain; 2015 Jun; 138(Pt 6):1642-57. PubMed ID: 25732184
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alpha-synuclein, lipids and Parkinson's disease.
    Ruipérez V; Darios F; Davletov B
    Prog Lipid Res; 2010 Oct; 49(4):420-8. PubMed ID: 20580911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.